---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-004971"
form_type: "8-K"
ticker: "GALT"
cik: "0001133416"
company_name: "GALECTIN THERAPEUTICS INC"
filed_at: "2025-02-18T23:59:59+00:00"
generated_at: "2026-05-26T14:17:28.427009+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Galectin reports 68.1% reduction in new varices with belapectin in U.S. patients from NAVIGATE trial

## Summary
- Per-protocol U.S. patients (n=186): 68.1% reduction in new varices with belapectin 2 mg vs placebo (p=0.02).
- New prevalence estimate: ~3 million U.S. adults with MASH cirrhosis and clinically significant portal hypertension.
- Top-line composite endpoint missed statistical significance in ITT (N=355); completer analysis had 49.3% reduction (p=0.04 revised).
- Full analysis ongoing; additional 36-month data expected by end of Q1 2025.

## SEC filing metadata
- accession: 0001140361-25-004971
- form_type: 8-K
- ticker: GALT
- cik: 0001133416
- company_name: GALECTIN THERAPEUTICS INC
- filed_at: 2025-02-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133416/000114036125004971/0001140361-25-004971-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133416/000114036125004971/ny20043588x1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-004971
- JSON: https://secwatch.observer/filing/0001140361-25-004971.json
- Plain text: https://secwatch.observer/filing/0001140361-25-004971.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.